Click on image or enlarge button to enlarge
Bcr Antibody (7C6): sc-103
- Bcr Antibody (7C6) is a mouse monoclonal IgG2a κ, cited in 14 publications, provided at 200 µg/ml
- raised against amino acids 686-698 mapping within an internal region of Bcr of human origin
- recommended for detection of Bcr/Abl p210 fusion protein in CML, but not Bcr/Abl p190, of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See Bcr (B-12): sc-28375 for Bcr antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Bcr Antibody (7C6). This work is in progress.
QUICK LINKS
SEE ALSO...
The Bcr gene, mapping on chromosome 22, was initially identified on the basis of its fusion with the c-Abl proto-oncogene on chromosome 9 resulting in the generation of the Philadelphia chromosome in 90-95% of patients with chronic myelogenous leukemia (CML). The Bcr gene encodes for the Breakpoint cluster region protein (Bcr). A consequence of this translocation is the generation of a Bcr/c-Abl mRNA encoding an activated c-Abl protein kinase. The Bcr gene has been shown to encode a GTPase-activating protein (GAP) specific for the Ras-related GTP-binding protein, Rac 1 p21. While it has been speculated that the Bcr protein may also stimulate Rac 2 p21 GTPase activity, it has no effect on Ras p21 or Rho p21 GTPases. It is of interest that the GAP domain of Bcr maps outside of the region that remains on chromosome 22 (Philadelphia chromosome) in CML.